한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제21권3호
  • /
  • Pages.193-207
  • /
  • 2011
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

비소세포폐암에 사용되는 항암화학요법의 요양급여기준 적절성 평가

Assessment of Appropriateness of Standard for Insurance Coverage on Chemotherapy used in Non-small Cell Lung Cancer (NSCLC)

  • 투고 : 2011.08.01
  • 심사 : 2011.09.06
  • 발행 : 2011.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The purpose of this study is to assess appropriateness of current standard for insurance coverage by Health Insurance Review & Assessment Service (HIRA) on chemotherapy used in the treatment of advanced non-small cell lung cancer (NSCLC), by reviewing a variety of clinical evidences, and thereby, if needed, to propose an updated evidence-based recommendations. Methods: We collected data from HIRA regarding on the insurance standard which includes the scope and conditions for coverage on systemic chemotherapy of NSCLC. We performed a search for clinical databases and examined the most current clinical evidence from clinical literature including various clinical practice guidelines. Based on the collected data the appropriateness of HIRA standard for insurance coverage of chemotherapy of NSCLC was assessed. Results: Collected data demonstrated that HIRA standard did not reflect the most current clinical practice and evidence. Some were inappropriately listed in HIRA formulary and accepted as a chemotherapy being covered by insurance, despite the lack of evidences of clinical efficacy or superiority over other chemotherapeutic agents or regimens. In addition, there seems to be a need for a modification on the standard for insurance coverage of certain newer chemotherapeutic agents based on the current accumulated data showing their clinical efficacy and benefits in the selected group of NSCLC patients. Therefore, we concluded that current HIRA standard for insurance coverage on chemotherapy of NSCLC needs to be revised and we proposed an updated recommendation based on these latest clinical evidences. Conclusion: The standard for insurance coverage of chemotherapy should be continually examined its appropriateness based on the most recent clinical evidences in a timely manner so as to provide the most effective and safe therapy to cancer patients.

키워드

참고문헌

  1. GLOBOCAN 2008. Cancer incidence and mortality worldwide in 2008, Available at http://globocan.iarc.fr/ factsheets/populations/factsheet.asp?uno=900. (Accessed on June 15, 2011).
  2. Jemal A, Siegel R, Xu J, et al., Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300. https://doi.org/10.3322/caac.20073
  3. National Cancer Information Center. Cancer Statistics. available at http://www.cancer.go.kr/cms/statics/incidence/ index.html. (Accessed on June 15, 2011).
  4. WHO. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press, 2004.
  5. In KH, Kwon YS, Oh IJ, et al., Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a Korean Lung Cancer Registry Study. Lung Cancer 2009; 64: 232-237. https://doi.org/10.1016/j.lungcan.2008.08.005
  6. D'Addario G, Fruh M, Reck M, et al., Metastatic nonsmall- cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v116-v119. https://doi.org/10.1093/annonc/mdq189
  7. Health Insurance Review & Assessment Service. 항암화학요법 등 공고내용 전문. Available at http://www.hira.or.kr/cms/ rd/rdg_infor/drugs/chemicals/publicly/1205230_11487.html (Accessed on April 21, 2011).
  8. Korean Association for the Study of Lung Cancer. 대한폐암학회 진료지침. 2nd edition. Available at http://www.lungca. or.kr/. (Accessed on Apr 7, 2011)
  9. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN $Guideline^{TM}$), Non-Small Cell Lung Cancer v3. 2011. Available at www.nccn.org. (Accessed on May 30, 2011).
  10. Azzoli CG, Baker S Jr, Temin S, et al., American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266. https://doi.org/10.1200/JCO.2009.23.5622
  11. Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007; 132: 1S-19S. https://doi.org/10.1378/chest.07-1860
  12. Lilenbaum RC, Herndon JE 2nd, List MA, et al., Singleagent versus combination chemotherapy in advanced nonsmall- cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005; 23: 190-196. https://doi.org/10.1200/JCO.2005.07.172
  13. Delbaldo C, Michiels S, Syz N, et al., Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA 2004; 292: 470-484. https://doi.org/10.1001/jama.292.4.470
  14. Georgoulias V, Ardavanis A, Agelidou A, et al., Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial. J Clin Oncol 2004; 22: 2602-2609. https://doi.org/10.1200/JCO.2004.11.004
  15. Negoro S, Masuda N, Takada Y, et al., Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003; 88: 335-341. https://doi.org/10.1038/sj.bjc.6600725
  16. Sederholm C, Hilerdal G, Lamberg K, et al., Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23: 8380-8388. https://doi.org/10.1200/JCO.2005.01.2781
  17. D'Addario G, Pintilie M, Leighl NB, et al., Platinum-based versus non-platinum-based chemotherapy in advanced nonsmall- cell lung cancer: A meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936. https://doi.org/10.1200/JCO.2005.03.045
  18. Hotta K, Matsuo K, Ueoka H, et al., Addition of platinum compounds to a new agent in patients with advanced nonsmall- cell lung cancer: A literature based meta-analysis of randomised trials. Ann Oncol 2004; 15: 1782-1789. https://doi.org/10.1093/annonc/mdh476
  19. Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non-small-cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006; 51: 335-345. https://doi.org/10.1016/j.lungcan.2005.11.001
  20. Rajeswaran A, Trojan A, Burnand B, et al., Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small-cell lung carcinoma: A systematic review of randomized controlled trials. Lung Cancer 2008; 59: 1-11. https://doi.org/10.1016/j.lungcan.2007.07.012
  21. Hotta K, Matsuo K, Ueoka H, et al., Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. Lung Cancer 2007; 57: 348-358. https://doi.org/10.1016/j.lungcan.2007.03.014
  22. Ardizzoni A, Boni L, Tiseo M, et al., Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-857. https://doi.org/10.1093/jnci/djk196
  23. Rosell R, Gatzemeier U, Betticher DC, et al., Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 2002; 13: 1539-1549. https://doi.org/10.1093/annonc/mdf332
  24. Schiller JH, Harrington D, Belani CP, et al., Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med 2002; 346: 92-98. https://doi.org/10.1056/NEJMoa011954
  25. Scagliotti GV, De Marinis F, Rinaldi M, et al., Phase III randomized trial comparing three platinum-based doultets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291. https://doi.org/10.1200/JCO.2002.02.068
  26. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four- Arm Coopertaive Study in Japan. Ann Oncol 2007; 18: 317-323.
  27. Alberola V, Camps C, Provencio M, et al., Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213. https://doi.org/10.1200/JCO.2003.12.038
  28. Comella P, Filippelli G, De Cataldis G, et al., Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: A phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 2007; 18: 324-330.
  29. Greco FA, Spigel Dr, Kuzur ME, et al., Paclitaxel/ carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: A phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer 2007; 8: 483-487. https://doi.org/10.3816/CLC.2007.n.032
  30. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991; 47: 87-98. https://doi.org/10.1093/oxfordjournals.bmb.a072464
  31. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. https://doi.org/10.1056/NEJMoa040938
  32. Parez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. https://doi.org/10.1126/science.1099314
  33. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957. https://doi.org/10.1056/NEJMoa0810699
  34. Yang CH, Fukuoka M, Mok TS, et al., Final overall survival (OS) results from a phase III, randomised, openlabel, first-line study of gefinitib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLCL) in Asia (IPASS). Ann Oncol 2010; 21: viii1-viii2 (suppl 8). https://doi.org/10.1093/annonc/mdp580
  35. Mitsudomi T, Morita S, Yatabe Y, et al., Gefinitib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128. https://doi.org/10.1016/S1470-2045(09)70364-X
  36. Keedy VL, Temin S, Somerfield MR, et al., American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol 2011; 29: 2121-2127. https://doi.org/10.1200/JCO.2010.31.8923
  37. Pao W, Miller VA, Politi KA, et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73. https://doi.org/10.1371/journal.pmed.0020073
  38. Sandler A, Grey R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. https://doi.org/10.1056/NEJMoa061884
  39. Forbes SA, Bhamra G, Bamford S, et al., The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc hum Genet 2008; chapter 10, unit 10.1.
  40. Eberhard DA, Johnson BE, Amler LC, et al., Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall- cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909. https://doi.org/10.1200/JCO.2005.02.857
  41. Miller VA, Riely GJ, Zakowski MF, et al., Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26: 1472- 1478. https://doi.org/10.1200/JCO.2007.13.0062
  42. Choi YL, Soda M, Yamashita Y, et al., EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739. https://doi.org/10.1056/NEJMoa1007478
  43. Forbes SA, Bhamra G, Bamford S, et al., The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet 2008;chapter 10, unit 10.1.
  44. Eberhard DA, Johnson BE, Amler LC, et al., Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall- cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909. https://doi.org/10.1200/JCO.2005.02.857
  45. Miller VA, Riely GJ, Zakowski MF, et al., Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26: 1472-1478. https://doi.org/10.1200/JCO.2007.13.0062
  46. Choi YL, Soda M, Yamashita Y, et al., EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739. https://doi.org/10.1056/NEJMoa1007478
  47. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180. https://doi.org/10.1016/S1470-2045(10)70087-5
  48. Christensen JG, Zou HY, Arango ME, et al., Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6: 3314-3322. https://doi.org/10.1158/1535-7163.MCT-07-0365
  49. Kwak EL, Bang YJ, Camidge R, et al., Anaplastic Lymphoma Kinase Inhibition in non-samll-cell lung cancer. N Engl J Med 2010; 363: 1693-1703. https://doi.org/10.1056/NEJMoa1006448
  50. Gridelli C, Ardizzoni A, Ciardiello F, et al., Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 430-440. https://doi.org/10.1097/JTO.0b013e318168c815
  51. Di Maio M, Chiodini P, Georgoulias V, et al., Meta-analysis of single-agent chmeotherapy compared with combination chemotherapy as second-line treatment of advnaced nonsmall- cell lung cancer. J Clin Oncol 2009; 27: 1836-1843. https://doi.org/10.1200/JCO.2008.17.5844
  52. Bang Y, Kwak EL, Shaw At, et al., Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small-cell cancer (NSCLC). J Clin Oncol 2010; 28: 18s (abstr 3)
  53. Scagliotti GV, Parikh P, von Pawel J, et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551. https://doi.org/10.1200/JCO.2007.15.0375
  54. Thatcher N, Chang A, Parikh P, et al., Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 20005; 366: 1527-1537. https://doi.org/10.1016/S0140-6736(05)67625-8
  55. Lee DH, Park K, Kim JH, et al., Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010; 16: 1307-1314. https://doi.org/10.1158/1078-0432.CCR-09-1903
  56. Gullen MH, Billingham LJ, Woodroffe CM, et al., Mitomycin, ifosfamide, and cisplatin in unresectable nonsmall- cell lung cancer; effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194. https://doi.org/10.1200/JCO.1999.17.10.3188
  57. Spiro S, Rudd R, Souhami R, et al., Chemotherapy versus supportive care in advanced non-small-cell lung cancer; improved survival without detriment to quality of life. Thorax 2004; 59: 828-836. https://doi.org/10.1136/thx.2003.020164
  58. Crino L, Clerici M, Figoli F, et al., Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomised trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.) Ann Oncol. 1995; 6: 342-353.
  59. Danson S, Middleton MR, O'Byrne KJ, et al., Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2003; 98: 542-553. https://doi.org/10.1002/cncr.11535
  60. Booton R, Lorigan P, Naderson H, et al., A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advnaced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006; 17: 1111-1119. https://doi.org/10.1093/annonc/mdl078
  61. Scagliotti GV, Fossati R, Torri V, et al., Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer inst 2003; 95: 1453-1461. https://doi.org/10.1093/jnci/djg059
  62. Song SY, Kim WS, Kim K, et al., Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer. Jpn J Clin Oncol. 2003; 33: 509-513. https://doi.org/10.1093/jjco/hyg100
  63. Montalar J, Morales S, Maestu I, et al., Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer. Lung Cancer 2001; 34: 305-311. https://doi.org/10.1016/S0169-5002(01)00255-0
  64. Souquet PJ, Tan EH, Rodrigues Pereira J, et al., GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small lung cancer patients. Ann Oncol 2002; 13: 1853-1861. https://doi.org/10.1093/annonc/mdf316
  65. Zhao Y, Chen Y, Ji H, Chu T, et al., Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer. Zhongguo Fei AiZa Zhi 2004; 7: 449-451.
  66. Kim YC, Lee SY, Cho HJ, et al., Effect of vinorelbine, ifosfamide and cisplatin combination chemotherapy in stage III-IV non-small-cell lung cancer. Cancer Research and Treatment 2002; 34: 352-356. https://doi.org/10.4143/crt.2002.34.5.352
  67. Cuomo AM, Robustelli della Cuna FS, baiardi P, et al., Three conventional-drug combination (ifosfamide, carboplatin, etoposide-ICE regimen) in advanced non-small cell lung cancer (NSCLC). J Chemother 2001; 13: 434-439. https://doi.org/10.1179/joc.2001.13.4.434
  68. Preti P, Poggi G, Cuomo AM, et al., Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC). J Chemother 1998; 10: 492-495. https://doi.org/10.1179/joc.1998.10.6.492
  69. Hsieh RK, Chang AY, Boros L, Asbury R. Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer. Am J Clin Oncol 1994; 17: 509-513. https://doi.org/10.1097/00000421-199412000-00012
  70. Li Dx, Chen XB. Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and arboplatin regimen for treatment of patients with advanced non-small cell lung cancer. Ai Zheng 2002; 21: 412-415.
  71. Lee G, Kim BD, Kang HJ, et al., Clinical Efficacy of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE) in advanced non-small cell lung cancer. Tuberc Respir Dis 2002; 52: 309-316. https://doi.org/10.4046/trd.2002.52.4.309
  72. Shepherd FA, Evans WK, Gross PE, et al., Ifosfamide, cisplatin, and etoposide(ICE) in the treatment of advanced non-small cell lung cancer. Semin Oncol 1992; 19(suppl 1): 54-58.
  73. Shirinian M, Lee JS, Dhingra HH, et al., Phase II study of cisplatin, ifosfamide with mesna and etoposide (PIE)chemotherapy for advanced non-small cell lung cancer. Semin Oncol 1992; 19(suppl 1): 49-53.
  74. Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. An LCSG Trial. Chest 1994; 106: 307S-309S.
  75. Hanna N, Shepherd FA, Fossella FV, et al., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597. https://doi.org/10.1200/JCO.2004.08.163
  76. Ciuleanu T, Brodowicz T, Zielinski C, et al., Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440. https://doi.org/10.1016/S0140-6736(09)61497-5
  77. Clarke SJ, Abratt R, Goedhals L, et al., Phase II trial of pemetrexed disodium in chemotherapy-naive patients with advanced non small cell lung cancer. Ann Oncol 2002; 13: 737-741. https://doi.org/10.1093/annonc/mdf115
  78. Rusthoven JJ, Eisenhauser E, Butts C, et al., Multitargeted antifolate LY231114 as first line chemotherapy for patients with advanced non small cell lung cancer: phase II study. J Clin Oncol 1999; 17: 1194-1199. https://doi.org/10.1200/JCO.1999.17.4.1194
  79. Lee HY, Ahn MJ, Park YH, et al., Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial. Lung Cancer 2009; 66: 338-343. https://doi.org/10.1016/j.lungcan.2009.02.008
  80. Gridelli C, Kaukel E, Gregorc V, et al., Single-agent pemetrexed or sequential pemetrexed/gemcitabine as frontline treatment of advanced NSCLC in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phaseⅡ trial, J Thorac Oncol, 2007; 2: 221-229. https://doi.org/10.1097/JTO.0b013e318031cd62
  81. The Cardiopulmonary Pathology Study Group. 심폐병리연구회 폐암환자 1천700여명 분석결과. Available at http://pps.pathology.or.kr/ (Accessed on July 11, 2011).
  82. Maemondo M, Inoue A, Kobayashi K, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388. https://doi.org/10.1056/NEJMoa0909530
  83. Zhou C, Wu YL, Chen G, et al., Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-smallcell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 2010; 21(suppl 8): abstr LBA13.
  84. Lee S, Rudd R, Khan I, et al., TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapynaive patient switch advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 2010; 28: 540s (suppl; abstr 7504). https://doi.org/10.1200/jco.2010.28.15_suppl.540
  85. Kim ST, Lee J, Kim JH, et al., Comparison of gefinitib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 2010; 116: 25-33.
  86. Lee JH, Lee KH, Ryu YJ, Chun EM, Chang JH. Comaprison of gefitinib and erlotinib for patients with advanced non-small-cell lung cancer. Tuberc Respir Dis 2009; 66: 280-287. https://doi.org/10.4046/trd.2009.66.4.280
  87. Moon DS, Jang TW, Oak CH, et al., Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer. Korean J Medicine 2009; 76: 179-180.
  88. Bae NR, Choi HJ, Lee BK, et al., Factors associated with effectiveness of and rash occurrence by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in patients with non-small cell lung cancer. Kor J Clin Pharm 2008; 18: 75-83.
  89. Chen YM, Whang-Peng J, Chen CM. First-line systemic therapy for metastatic non-small-cell lung cancer-A review. J Exp Clin Med 2011; 3: 116-120, in press. https://doi.org/10.1016/j.jecm.2011.04.008
  90. Akerley W, Boucher KM, Bentz JS, et al., A Phase II study of erlotinib as inital treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol 2009; 4: 214-219. https://doi.org/10.1097/JTO.0b013e3181943bb9
  91. Xu XH, Su J, Fu XY, et al., Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small lung cancer. Cancer Chemother Pharmacol. 2011; 67: 475-479. Epub 2010 Sep 16. https://doi.org/10.1007/s00280-010-1450-6
  92. Pirker R, Periera JR, Szczesna A, et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open label randomised phase III trial. Lancet 2009; 373: 1525-1531. https://doi.org/10.1016/S0140-6736(09)60569-9
  93. Lin H, Jiang J, Liang X, et al., Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: A systematic review and metaanalysis. Lung Cancer 2010; 70: 57-62. https://doi.org/10.1016/j.lungcan.2010.01.009
  94. Cho BC, Kim JH, Soo RA, et al., The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J 2010; 51: 1-8. https://doi.org/10.3349/ymj.2010.51.1.1
  95. Tsao AS. Cetuximab combined with chemotherapy in nonsmall cell lung cancer. Community Oncol 2010; 7 :17-22. https://doi.org/10.1016/S1548-5315(11)70384-9
  96. Belani CP, Lee JS, Socinski MA, et al., Randomized phase III trial comparing cisplatin-etoposide to carboplatinpaclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005; 16: 1069-1075. https://doi.org/10.1093/annonc/mdi216
  97. Itri LM, Gralla RJ. A review of etoposide in patients with non-small-cell lung cancer (NSCLC). Cancer Treat Rev 1982; 9: 115-118. https://doi.org/10.1016/S0305-7372(82)80090-X
  98. Kakolyris S, Samonis G, Koukourakis M, et al., Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Concol 1998; 21: 505-508. https://doi.org/10.1097/00000421-199810000-00018
  99. Sorio R, Toffoli G, Crivellari D, et al., Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study. J Chemother 2006; 18: 188-191. https://doi.org/10.1179/joc.2006.18.2.188
  100. Kim YH, Yoh K, Niho S, et al., Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer. Respir Med 2010; 104: 434-439. https://doi.org/10.1016/j.rmed.2009.10.020